Switzerland’s pharmaceutical company, Novartis AG has opened its innovation hub, Novartis Biome Sub-Saharan Africa in Nairobi. This is with an ambitious goal of doubling its patient reach in the region by 2022 and increasing it five-fold by 2025.
“Our goal is to provide every patient in SSA with affordable access to high-quality medicines and to ultimately transform healthcare in the region. For this, innovation and digital technologies have an immense potential to contribute, and with cross-sectoral partnerships, we can truly maximize the impact on the health of our people,” said Racey Muchilwa, President and Head, Novartis Sub-Saharan Africa.
The hub will focus on cross-sectoral partnerships to accelerate innovative approaches to increase affordable access to high-quality medicines and sustainably strengthen health systems.
The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products.
In addition, it uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism.
The Novartis Biome SSA will also continue to build on its partnership with Medtronic Labs to deliver end-to-end care for hypertension and diabetes patients by seeking to scale their model across the continent.